Eurofins Viracor, Inc., Lee’s Summit, Mo., has launched the Coronavirus (COVID-19) SARS-CoV-2 inSight T Cell Immunity test, which delivers an understanding of a patient’s response to viral antigens, providing critical insight to aid in treatment decisions. The test measures CD4+ and CD8+ T Cell response to the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins to independently evaluate cell-mediated immunity to Coronavirus SARS-CoV-2 that causes COVID-19.
Utilizing flow cytometry and intracellular cytokine staining, SARS-CoV-2 inSight testing could be an important tool for evaluating immunological memory to the SARS-CoV-2 virus, and even indicate a level of protection from further infection.
SARS-CoV-2 inSight testing joins a robust menu of COVID-19 testing, including the recently launched cPass Coronavirus SARS-CoV-2 Neutralizing Antibody test. When used in combination with the Neutralizing Antibody test, results from the tests could help physicians evaluate two areas of our adaptive immune system that can indicate immunity. When neutralizing antibody response begins to diminish months after exposure to the virus or vaccine, the presence of T cell immunity may signify long-term immunity.
